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Abstract 
Limb-salvage for primary malignant bone tumors in pediatric patients presents a unique challenge when resection 
includes an active physis. Early expandable prostheses required open surgical procedures to achieve lengthening. 
Newer prostheses are capable of achieving expansion without open procedures through the use of an electromag-
netic field. This study reports our results with 90 consecutive expansion procedures using the Repiphysis® prosthesis. 
We retrospectively reviewed the records of 20 patients (22 limbs) who underwent limb-salvage using the Repiphy-
sis® prosthesis from 2003 to 2015. There were 9 males and 11 females with a mean age of 9 years and 9 months 
(6–16 years). Reconstruction included the distal femur in 11 cases, total femur in four, proximal tibia in three, proximal 
humerus in three, and total humerus in one. Complications were reviewed and functional scores were recorded using 
the MSTS/ISOLS system. Five patients had a second prosthesis implanted during the course of the study for a total 
of 27 prostheses. The mean follow-up was 57 (6–148) months. Four patients have not been expanded: three due to 
death prior to lengthening, and one patient who has not yet developed a leg length discrepancy. Ninety consecutive 
expansion procedures were performed in 18 limbs in 16 patients. A mean of 9 (5–20) mm was gained per expansion 
and 4.8 cm per patient who has undergone expansion to date. Seven patients have reached skeletal maturity and 
have been converted to an adult endoprosthesis. These patients averaged 8 expansions per patient and a mean of 7.4 
(1.8–12.9) cm in length gained. There were 15 complications in 11 patients including one dislocation, one contracture, 
four cases of aseptic loosening, five structural failures (three expansion mechanism failures and two tibial fractures), 
three deep infections, and one case of local recurrence. The mean MSTS score was 80 % (37–97 %) and the limb reten-
tion rate was 95 %. The results of this study are comparable to previous studies involving non-invasive prostheses. This 
study hopefully provides additional data for clinicians to consider when faced with limb threatening sarcomas in the 
immature skeleton.
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Background
Limb salvage became popularized following detailed 
reports by Mankin and Marcove in 1976 (Mankin et  al. 
1976; Marcove 1976). These papers, in conjunction with 
the classic report by Simon and Rougraff showing no 
survival or local control advantage to amputation, paved 
the way for limb preservation procedures (Rougraff et al. 
1994).
Limb-salvage in pediatric patients poses an additional 
challenge compared to adults due to the presence of an 
open physis. In order to obtain a wide surgical margin, 
the growing physis must often be removed, creating a 
limb-length discrepancy. Lewis published one of the first 
reports on the use of expandable endoprostheses to help 
minimize limb length discrepancy (Lewis 1986; Kenan 
and Lewis 1991). These designs incorporated the use of 
a screw extension mechanism, where a chuck key would 
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be inserted through an incision to expand the length of 
the prosthesis and thus the extremity, while later meth-
ods utilized modular body segments to achieve length-
ening, requiring open surgical procedures (Lewis 1986; 
Kenan and Lewis 1991; Eckardt et  al. 2000; Neel and 
Letson 2001). Jeys reported on periprosthetic infections 
in orthopaedic oncology conditions and found the use 
of expandable prostheses in children as a significant risk 
factor with a rate of 18 %, (p = 0.007), and that infection 
was increased as much as 5 % per lengthening procedure 
(Jeys et  al. 2005). In order to accurately address limb 
surgery in children with sarcomas the authors feel they 
should mention two other techniques, amputation and 
arthroplasty. The former has few surgical side effects with 
decreased functional scores (Eckardt et  al. 1985; Simon 
et al. 1986). Rotationplasty in the growing child has excel-
lent function with few surgical complications (Hardes 
et al. 2003). Acceptance of the physical appearance of this 
option has limited its use (Veenstra et al. 2000).
The Repiphysis® non-invasive expandable prosthesis 
(Microport Orthopedics, Arlington, Tennessee, USA, 
originally manufactured as the Phenix prosthesis, Phe-
nix Medical, Paris, France) was the first endoprosthesis 
design to introduce the concept of a non-invasive expan-
sion procedure involving the use of an electromagnetic 
field (Wilkins and Soubeiran 2001; Neel et al. 2003; Gupta 
et  al. 2006). This implant allows for a serial number of 
lengthenings to be performed without an open surgical 
procedure. The closed lengthenings avoid incisions. This 
in turn avoids all those problems associated with open 
surgery, blood loss and acute lengthenings. Acute length-
enings with sudden elongation, may produce neuropathy, 
vascular compromise, and contracture (Herzog and Hefti 
1992; Janovec and Polách 1990) The aim of the current 
study is to report our experience with 20 patients treated 
with the Repiphysis® non-invasive expandable prosthesis 
for limb-salvage.
Methods
We retrospectively reviewed the records of 20 consecu-
tive patients who underwent implantation of the Repiph-
ysis® noninvasive expandable prosthesis at our institution 
from 2003 to 2015. Minimum follow-up was 14 months 
unless patients died of disease or the implant failed prior. 
We have previously reported on early results of the first 
12 of these patients and present them with longer term 
follow-up and additional lengthening procedures (Beebe 
et  al. 2010) in addition to eight new patients. Data col-
lected included patient demographics, pathology, 
lengthening, total expansion length, complications, and 
functional status. Implantation of the Repiphysis® pros-
thesis is indicated for limb-salvage in skeletally imma-
ture patients in which wide resection includes removal of 
an active physis and the patient is left with a projected 
limb-length discrepancy of ≥6  cm (Harvey et  al. 2010; 
Holm et  al. 1994; Papaioannou et  al. 1982; Song et  al. 
1997; Stanitski 1999). Growth remaining was determined 
according to the standard methods after bone age was 
assessed (Anderson et al. 1963; Dimeglio 2001). For use 
in the humerus, the Repiphysis® was discussed with the 
patient and family as a limb-salvage option and Com-
passionate Use Guidelines were followed with our Insti-
tutional Review Board (IRB) permission. Patients were 
indicated for expansion when chemotherapy was com-
plete and a limb-length discrepancy of ≥1 cm was noted 
clinically. Functional scores were recorded using the 
MSTS/ISOLS functional scoring system (Enneking et al. 
1993). Scores were obtained upon completion of rehabili-
tative therapy, or at most recent follow-up if therapy was 
not completed.
When the prosthesis is exposed to an external ring 
producing an electromagnetic field, the heat softens the 
outer polyethylene cylinder, thus unlocking the flared 
trumpet and permitting the prosthesis to expand as the 
spring decompresses and allows the inner tube to slide 
within the polyethylene cylinder (Wilkins and Soubeiran 
2001) All expansions are performed with conscious seda-
tion or general anesthesia in the operating room with 
fluoroscopic guidance, using a C-arm, radiolucent table, 
radiolucent ruler, and goniometer. Expansion proce-
dures typically take 20 min. The radiofrequency signal is 
applied in pre-set “pulses” under fluoroscopic guidance 
until the desired lengthening is achieved. Upon conclu-
sion of the lengthening, the metallic trumpet cools down 
and locks the prosthesis back in place in a new portion of 
the polyethylene cylinder (Fig. 1a, b).
Results
The results are summarized in Table 1. Twenty patients 
had 22 sites treated with 27 non-invasive expandable 
endoprostheses from 2003 to 2015. Two patients (16 and 
20) had a second osteosarcoma: 1 in the contralateral 
femur, 1 in the ipisilateral humerus. The diagnosis was 
osteosarcoma in 18 patients and Ewing’s sarcoma in two. 
There were 9 males and 11 females studied with a mean 
age of 9  years and 9  months (6–16  years) at the index 
procedure and a mean follow-up of 57 (6–148) months, 
with an endpoint of death or latest follow-up. Of 22 limbs 
in 20 patients, 17 were treated at the author’s institution 
primarily with Repiphysis. Two patients (14 and 17) were 
treated at outside institutions and presented to our insti-
tution after a failed implant. One patient had an earlier 
invasive expandable prosthesis prior to the availability of 
Repiphysis, which was explanted following deep infec-
tion from an open lengthening. This patient then had a 
Repiphysis implanted following eradication of infection 
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(patient 7). One patient initially had an intercalary allo-
graft, which fractured and was revised with a Repiphysis 
(patient 16a).
Reconstruction included the distal femur in 11 cases, 
total femur in four, proximal tibia in three, proxi-
mal humerus in three, and total humerus in one. Five 
patients had a second endoprosthesis implanted during 
the study period for a total of 27 non-invasive expand-
able prostheses in our 20 patient cohort. Of these five 
second implants, one was for a deep infection in which 
the original Repiphysis® was removed and a new one re-
implanted after eradication of the infection (Patient 13), 
and four implants were exchanged for a new prosthe-
sis after they had reached their maximum elongation to 
permit continued expansion (Patients 9, 14, 15 and 16a). 
Generally the authors waited until the patient required 
an expansion or the implant became symptomatic before 
explant and re-implantation of a second new prosthesis.
At the time of latest follow-up, 65  % of patients are 
alive (11 CDF, 7 DOD, 1 AWD, 1 NED). Ninety consecu-
tive expansion procedures were performed in 18 limbs in 
16 patients. The patients who have not had any expan-
sions include three patients who died of disease prior to 
lengthening (Patients 8, 11 and 17) and one patient who 
has not yet established a limb-length discrepancy war-
ranting expansion (Patient 19). Two patients (14, 15) had 
a second prosthesis that underwent additional expansion. 
A mean of 9 (5–20)  mm was gained per expansion and 
4.8 cm per patient who has undergone expansion to date.
Conversion to adult implants
Among the prostheses which have undergone expansion: 
eight are still undergoing expansion procedures, three 
patients have died of disease prior to reaching skeletal 
maturity (Patients 3, 10 and 13), and seven patients have 
reached skeletal maturity and been converted to a non-
expandable adult endoprosthesis (Patients 1, 2, 4, 5, 12, 14, 
and 15) (Fig. 1c). Among those who have reached skeletal 
maturity, there were an average of 8 expansions per patient 
and a mean length gained of 7.4 (1.8–12.9) cm. Six of the 
seven patients have no limb length discrepancy. The seventh 
patient had a proximal humerus replacement, which experi-
enced an expansion mechanism failure (Fig. 2). Because the 
patient was nearing skeletal maturity, revision included con-
version to an adult endoprosthesis. The patient has a 2.5 cm 
limb length discrepancy, which is not clinically sympto-
matic, with an MSTS score of 87 % (Patient 12).
During the course of our study period we experienced 
15 complications (56  %). We classified our complica-
tions according to the five modes of failure for tumor 
endoprostheses (Henderson et  al. 2011; Palumbo et  al. 
2011) (Table 2). There were two type I (soft-tissue) fail-
ures. A patient with a distal femoral prosthesis under-
went an arthroscopic release of the quadriceps due to 
an extensor mechanism contracture (Patient 5). Another 
patient had initially presented with a custom expand-
able humeral prosthesis that became infected and was 
treated with an explant, IV antibiotics, and a spacer fol-
lowed by re-implantation using a Repiphysis®. The Repi-
physis® elbow became stiff after six lengthenings, with a 
flexion contracture and a proximal radial-ulnar joint dis-
location resulting from previous proximal ulnar physeal 
arrest, secondary to infection (Patient 7, Fig.  3). There 
were four type II (aseptic loosening) failures in which 
there was evidence of loosening of the stem of the pros-
thesis, occurring at a mean of 50.5 (23–83) months after 
initial surgery (Patients 1, 2, 15 and 16a, Fig. 4). Two of 
these were at skeletal maturity and revised with an adult 
prosthesis, and the other two were revised with a second 
Repiphysis®. Five patients experienced a type III (struc-
tural) failure. There were three failures of the expansion 
Fig. 1 Patient with a femoral prosthesis prior to undergoing any 
expansion procedures (a) and at the maximum growth potential for 
the implant (b)
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mechanism of the prosthesis (Patients 9, 12 and 14). 
Patients 9 and 12 were converted to an adult prosthesis 
and patient 14 was revised to a second Repiphysis®. The 
other two type III failures were periprosthetic tibial frac-
tures, which were managed non-operatively (Patients 2 
and 9, Fig.  5a–d). Three patients experienced a type IV 
(infection) failure (Patients 5, 13, and 14, Fig. 6a). These 
were treated by removal of the implant and placement 
of a custom antibiotic spacer (Fig.  6b–d), IV antibiotics 
for six weeks, then oral antibiotics for an additional six 
weeks, with subsequent re-implantation upon eradica-
tion of the infection. One of these patients had a second 
Repiphysis® re-implanted (Fig.  6e), and the other two 
were converted to an adult prosthesis. All of these 
patients were able to achieve limb length equality. Finally, 
one patient who did not have any expansions experienced 
a type-V (tumor progression) failure and required a hip 
disarticulation (Patient 11). The overall limb preservation 
rate in our patients was 95  % (21/22 limbs). The mean 
MSTS score was 80 % (37–97 %).
Discussion
Over the past 30 years there have been several expand-
able implant systems designed to be used in the growing 
Types of failure: soft-tissue (I), aseptic loosening (II), structural failure (III), infection (IV), tumor progression (V)
Patients 1–12 were reported on in previous study
Patients 16 and 20 had diagnosis of Osteosarcoma at two different sites
DOD dead of disease, NED no evidence of disease, AWD alive with disease, CDF continuously disease free
A Indicates that the patient had second Repiphysis expandable prostheses at same site
B Patient presented with a second bone lesion without pulmonary metastasis
C Indicates patients initially treated at an outside institution, and presented to our institution after failed implant


























1 9 + 8 Osteosarcoma IIB R Prox Tibia 2 1.8 144 Yes II CDF Aseptic loosening 93
2 9 + 10 Osteosarcoma IIB R Dist Femur 10 10 148 Yes II, III NED Aseptic loosening 
and tibial fracture
77
3 9 + 11 Osteosarcoma IIB R Dist Femur 1 2 22 No DOD 67
4 8 + 10 Osteosarcoma IIB L Prox 
Humerus
6 5.8 116 Yes CDF 93
5 11 + 2 Ewing’s Sar-
coma
IIB L Dist Femur 8 7.9 137 Yes I, IV CDF Contracture, infec-
tion
97
6 10 + 8 Osteosarcoma IIB L Dist Femur 6 7 61 No CDF 77
7 16 Ewing’s Sar-
coma
IIB L Prox 
Humerus
6 5.5 75 No I CDF Contracture/dislo-
cation
93
8 7 + 9 Osteosarcoma IIB L Dist Femur 0 0 10 No DOD 70
9A 12 + 1 Osteosarcoma IIB L Prox Tibia 5 4.5 64 No III × 2 DOD Prosthesis failure, 
tibial fracture
93
10 10 + 6 Osteosarcoma III L Dist Femur 2 2.2 27 No DOD 80
11 12 + 9 Osteosarcoma IIB L Dist Femur 0 0 12 No V DOD Hip disarticulation 80
12 7 Osteosarcoma IIB L Prox 
Humerus
8 6.9 71 Yes III CDF 87
13A 9 + 7 Osteosarcoma IIB L Dist Femur 4 4 41 No IV DOD Infection 63
14A,C 9 + 11 Osteosarcoma IIB L Dist Femur 9 6.8 67 Yes III, IV CDF Prosthesis failure, 
Infection
87
15A 9 + 4 Osteosarcoma IIB L Dist Femur 14 12.9 63 Yes II CDF Aseptic loosening 90
16aA 9 + 2 Osteosarcoma IIB R Dist Femur 1 1 54 No II CDF Aseptic loosening 93
16b 11 Osteosarcoma IIB L Dist Femur 1 1 30 No CDF 83
17C 12 Osteosarcoma IIB L Dist Femur 0 0 6 No DOD 47
18 6 Osteosarcoma IIB R Dist Femur 2 2 30 No CDF 90
19 7 + 1 Osteosarcoma IIB L Prox Tibia 0 0 14 No CDF 37
20a 6 + 9 Osteosarcoma IIB R Dist Femur 3 2.3 37 No AWD 83
20bB 7 + 6 Osteosarcoma III R Prox 
Humerus
2 1.7 17 No AWD 80
Page 5 of 9Benevenia et al. SpringerPlus  (2015) 4:793 
child. In the 1990’s, new prostheses were developed that 
allowed non-invasive lengthening through the applica-
tion of an external electromagnetic field (Wilkins and 
Soubeiran 2001; Neel et al. 2003; Baumgart et al. 1997).
The Repiphysis® prosthesis, originally manufactured 
as the Phenix® prosthesis in France, was the first of these 
non-invasive expandable implants used in the United 
States. Early experience with the prosthesis was reported 
by Wilkins and Souberian (Wilkins and Soubeiran 2001), 
who examined the functional outcomes after 21 length-
enings in six patients. One of the major advantages of the 
Repiphysis® over earlier designs is that the non-invasive 
nature of the expansion procedure permits frequent 
expansions of smaller increments with minimal patient 
discomfort. This decreases the risk of stretch injury 
to nerves and blood vessels and resection of soft tissue 
and pseudocapsule around the prosthesis. It avoids an 
open surgical procedure each time expansion is neces-
sary. Although there were no complications attributed 
to lengthening procedures themselves, Wilkins and Sou-
berian reported two mechanical complications in one 
patient (Wilkins and Soubeiran 2001).
In 2003, a multicenter study by Neel et al. (Neel et al. 
2003) reported the results of 60 expansions in 18 Repi-
physis® prostheses implanted in 15 patients. Mean 
follow-up was 21.5 (12–33) months. There were no com-
plications associated with lengthening procedures them-
selves. They had a mean of 3.7  cm of lengthening and 
MSTS scores averaging 90  %, but the prostheses were 
subject to a 44 % complication rate including six prosthe-
sis fractures and two aseptic loosenings (Neel et al. 2003). 
Longer-term studies using the Repiphysis® prosthesis 
have produced similar results, with mean MSTS scores 
ranging from 67 to 90 % and patients gaining a mean of 
2.5–3.9 cm of lengthening (Saghieh et al. 2010; Cipriano 
et al. 2015).
The Stanmore Juvenile Tumour System (JTS, Stanmore 
Implants Worldwide, Stanmore, UK) also incorporates 
a magnetic field for non-invasive expansion after tumor 
resection in skeletally immature patients. In contrast to 
the Repiphysis® design, the JTS contains a magnetic disc, 
a gearbox, and a power screw embedded within the shaft 
of the prosthesis. When exposed to an external electro-
magnetic field the implant is expanded at a fixed rate. 
One of the limitations of the JTS is that the use of MRI in 
these patients is contraindicated due to interference with 
the electromagnetic motor (Gupta et al. 2006).
Hwang et al. reported on the use of the JTS in a series 
of 25 patients published in 2012 (Hwang et  al. 2012). 
They reported a mean of 3.2  cm of lengthening with 
a mean MSTS score of 85 % and a complication rate of 
38  %. Other studies have reported similar experience 
with the JTS, with a mean 3.7–4.5  cm of lengthening, 
MSTS scores ranging from 82 to 87 %, and follow-up of 
41.2 (22–104) and 48 (23–146)  months (Picardo et  al. 
2012; Henderson et al. 2012).
The current study reports the results of 20 pedi-
atric patients treated at 22 sites with 27 Repiphysis® 
Fig. 2 Breakage of the expansion mechanism in a proximal humeral 
prosthesis
Table 2 Five modes of tumor prosthesis failure according to Henderson et al. (2011, 2012)
Type of failure Description No. of pts
I Soft-tissue: A functional deficiency of the soft tissue attachments about the implant. Includes instability, tendon rupture, 
and wound dehiscence
2
II Aseptic loosening: Clinical and radiographic evidence of loosening of the prosthesis 4
III Structural failure: Failure of either the implant or surrounding bone. Includes fractures of the prosthesis, periprosthetic 
fractures, and a deficient bony supporting structure
5
IV Infection: Deep infection requiring removal of the implant 3
V Tumor progression: Re-operation due to local tumor recurrence or metastatic disease progression 1
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Fig. 3 A contracture/dislocation in a patient with a humeral endo-
prosthesis
Fig. 4 Aseptic loosening of the proximal stem in a femoral endopros-
thesis
Fig. 5 Periprosthetic tibial fractures in patients with a distal femoral 
prosthesis (a) and a proximal tibial prosthesis (b) which healed with 
non-operative management (c, d)
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prostheses with a mean follow-up of 57  months. This 
is subject to all the inherent limitations of a retrospec-
tive study design. The results are comparable to previ-
ously published studies involving the Repiphysis® in 
terms of both function and complications. The overall 
limb-salvage rate was 95 %, with one patient requiring a 
hip disarticulation for an oncologic complication (local 
recurrence). On average, patients gained 9 mm of length 
per expansion and 4.6 cm per patient who has undergone 
lengthening. So far, those that reached skeletal maturity 
were lengthened by a mean of 7.4  cm. To the author’s 
knowledge, there has been no other non-invasive study 
with this amount of expansion and only one other series 
with greater reported mean expansion which used open 
Fig. 6 a Radiographic evidence of septic loosening of a femoral prosthesis. b, c Removal of the implant and placement of an antibiotic spacer 
consisting of an intramedullary nail (b) covered in antibiotic cement (c). d A radiograph of the antibiotic spacer after removal of the prosthesis. e 
Reimplantation of the prosthesis after eradication of the infection
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lengthening techniques (Schiller et  al. 1995). This is the 
largest study cohort of Repiphysis among similar pub-
lished studies (Beebe et  al. 2010; Cipriano et  al. 2015; 
Gupta et  al. 2006; Neel et  al. 2003; Saghieh et  al. 2010; 
Wilkins and Soubeiran 2001).
The mean MSTS score in this study was 80  %, which 
falls between the 67  % and 90  % MSTS scores reported 
in previous studies. There was only one case of limb 
length discrepancy, 2.5  cm limb length discrepancy in 
the humerus of patient 12. The complication rate was 
56 % (15 complications in 27 prostheses); 2 type I, 4 type 
II, 5 type III, 3 type IV, and 1 type V. Our infection rate 
is comparable to previously published studies involv-
ing Repiphysis® and with both traditional invasively 
expandable endoprostheses, which have demonstrated an 
infection rate up to 18  % (Wilkins and Soubeiran 2001; 
Saghieh et  al. 2010; Cipriano et  al. 2015; Hwang et  al. 
2012; Picardo et al. 2012).
A limitation of the Repiphysis® relative to the JTS 
is that the Repiphysis® requires conversion to a non-
expandable adult prosthesis at skeletal maturity while the 
JTS is designed to be a permanent implant. A limitation 
of the JTS relative to the Repiphysis® is that patients are 
unable to undergo an MRI. Given the value of MRI for re-
staging in this patient population, the use of devices that 
prohibit this imaging modality must be carefully consid-
ered (Heindel et  al. 2014; Nascimento et  al. 2014). Fur-
thermore, it is not known whether a patient will be able 
to function with a pediatric size endoprosthesis in the 
long-term.
In conclusion, the Repiphysis® prosthesis (Microport 
Orthopedics, Arlington, Tennessee, USA) is an option for 
limb-salvage in skeletally immature patients and has sim-
ilar drawbacks to other designs. It requires conversion to 
an adult prosthesis with a limb retention rate of 95 % and 
has a mean lengthening of 7.4 cm at maturity. Given the 
complications associated with the use of this prosthesis, 
as well as other expandables, the authors caution against 
uninformed use and recommend full and complete dis-
closure of all other treatment options with patients and 
their families before surgery.
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